Timing of Local and Distant Failure in Resected Lung Cancer Implications for Reported Rates of Local Failure

被引:80
作者
Boyd, Jessamy A. [1 ]
Hubbs, Jessica L. [1 ]
Kim, Dong W. [1 ]
Hollis, Donna [2 ]
Marks, Lawrence B. [3 ]
Kelsey, Chris R. [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Canc Ctr Biostat, Durham, NC 27710 USA
[3] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC USA
关键词
Non-small cell lung cancer; Local recurrence; Distant recurrence; Patterns of failure; STAGE-I; RECURRENCE; RADIOTHERAPY;
D O I
10.1097/JTO.0b013e3181c20080
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Most adjuvant lung cancer trials only report first sites of failure. The relative timing of local (i.e., local/regional) versus distant recurrence after surgery could potentially affect reported rates of local failure. We assessed this phenomenon in a large group of patients undergoing Surgery for early-stage lung cancer. Methods: This institutional review board-approved retrospective Study identified all patients who underwent surgery at Duke University Medical Center for pathologic stages I to 11 non-small cell lung cancer between 1995 and 2005. Medical records and pertinent radiographs were reviewed to assess for local and distant sites of recurrence. Both first and subsequent failures were examined. The time interval between surgery and date of local and/or distant failure was compared using the Mann-Whitney U test. Results: Of 975 patients undergoing surgery, 250 patients developed recurrent disease (43 local only, I 10 distant only, and 97 both). The median time from Surgery to local failure was 13.9 months (range, 1-79). The median time to distant failure was 12.5 months (range, 1-79 months). These were not significantly different (P = 0.34). Among 97 patients who experienced both local and distant failure, 72 (74%) failed at both sites simultaneously, 19 (20%) failed at local sites first, and 6 (6%) failed at distant sites first. Conclusions: The time interval from surgery to either local or distant failure is not significantly different. Patterns of failure analyses in which only first sites of failure are scored will underestimate the frequency of local recurrence. Nevertheless, the magnitude of this error is expected to be small.
引用
收藏
页码:211 / 214
页数:4
相关论文
共 14 条
  • [1] [Anonymous], 1995, Ann. Thorac. Surg, DOI 10.1016/0003-4975
  • [2] SITES OF RECURRENCE IN RESECTED STAGE-I NON-SMALL-CELL LUNG-CANCER - A GUIDE FOR FUTURE STUDIES
    FELD, R
    RUBINSTEIN, LV
    WEISENBERGER, TH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (12) : 1352 - 1358
  • [3] A study of postoperative radiotherapy in patients with non-small-cell lung cancer: A randomized trial
    Feng, QF
    Wang, M
    Wang, LJ
    Yang, ZY
    Zhang, YG
    Zhang, DW
    Yin, WB
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (04): : 925 - 929
  • [4] Cancer statistics, 2007
    Jemal, Ahmedin
    Siegel, Rebecca
    Ward, Elizabeth
    Murray, Taylor
    Xu, Jiaquan
    Thun, Michael J.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) : 43 - 66
  • [5] A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
    Kato, H
    Ichinose, Y
    Ohta, M
    Hata, E
    Tsubota, N
    Tada, H
    Watanabe, Y
    Wada, H
    Tsuboi, M
    Hamajima, N
    Ohta, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (17) : 1713 - 1721
  • [6] Local Recurrence After Surgery for Early Stage Lung Cancer An 11-Year Experience With 975 Patients
    Kelsey, Chris R.
    Marks, Lawrence B.
    Hollis, Donna
    Hubbs, Jessica L.
    Ready, Neal E.
    D'Amico, Thomas A.
    Boyd, Jessamy A.
    [J]. CANCER, 2009, 115 (22) : 5218 - 5227
  • [7] Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer
    Lardinois, D
    Suter, H
    Hakki, H
    Rousson, V
    Betticher, D
    Ris, HB
    [J]. ANNALS OF THORACIC SURGERY, 2005, 80 (01) : 268 - 275
  • [8] Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    Le Chevalier, T
    Arriagada, R
    Le Péchoux, C
    Grunenwald, D
    Dunant, A
    Pignon, JP
    Tarayre, M
    Abratt, R
    Arriagada, R
    Bergman, B
    Gralla, R
    Grunenwald, D
    Le Chevalier, T
    Orlowski, T
    Papadakis, E
    Pinel, MIS
    Araujo, C
    Della Torre, H
    de Solchaga, MM
    Abdi, E
    Blum, R
    Ball, D
    Basser, R
    De Boer, R
    Bishop, J
    Brigham, B
    Davis, S
    Fox, D
    Richardson, G
    Wyld, D
    Pirker, R
    Humblet, Y
    Delaunois, L
    Van Meerbeeck, JP
    Germonpre, P
    Vansteenkiste, J
    Nackaerts, K
    Pinel, MIS
    Vauthier, G
    Younes, RN
    Arriagada, R
    Baeza, R
    Carvajal, P
    Kleinman, S
    Orlandi, L
    Castro, C
    Godoy, J
    Kosatova, K
    Gaafar, R
    Azarian, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (04) : 351 - 360
  • [9] Luzzi L, 2003, J CARDIOVASC SURG, V44, P119
  • [10] Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma
    Sawyer, TE
    Bonner, JA
    Gould, PM
    Foote, RL
    Deschamps, C
    Lange, CM
    Li, HZ
    [J]. ANNALS OF THORACIC SURGERY, 1999, 68 (04) : 1171 - 1176